Lymph node positive head and neck carcinoma after curative radiochemotherapy: A long lasting debate on elective post-therapeutic neck dissections comes to a conclusion

2013 ◽  
Vol 17 (4) ◽  
pp. 323-331 ◽  
Author(s):  
R.M. Hermann ◽  
H. Christiansen ◽  
R.M. Rödel
2021 ◽  
Vol 1 (3) ◽  
pp. 165-172
Author(s):  
YU SUZUKI ◽  
KEIICHI JINGU ◽  
EIICHI ISHIDA ◽  
TAKAKI MURATA ◽  
MASAKI KUBOZONO

Background: The standard irradiation dose to the elective lymph node area (ELNA) in locally patients with advanced head and neck squamous cell carcinoma (LA-HNSCC) to control lymph node micrometastases (LN-MM) has not changed since it was empirically determined in the 1950s. We investigated the optimal irradiation dose for controlling LN-MM in ELNAs. Patients and Methods: The pattern of recurrence of LA-HNSCC was retrospectively evaluated in patients who underwent concurrent chemoradiotherapy with cisplatin or radiation therapy alone. Results: In total, 162 patients were enrolled. The median observation period was 34 months. No recurrence was found in ELNAs. After propensity score matching, a cisplatin dose of ≥200 mg/m2 yielded a significantly higher overall survival rate (p≤0.001) and locoregional control rate (p=0.034) than did a dose of <100 mg/m2. Conclusion: CCRT with a cisplatin dose of ≥200 mg/m2 can reduce the irradiation dose to 40-44 Gy at 2 Gy per fraction to control LN-MM.


Cancer ◽  
2008 ◽  
Vol 112 (5) ◽  
pp. 1076-1082 ◽  
Author(s):  
Anamaria R. Yeung ◽  
Stanley L. Liauw ◽  
Robert J. Amdur ◽  
Anthony A. Mancuso ◽  
Russell W. Hinerman ◽  
...  

2020 ◽  
Vol 122 (6) ◽  
pp. 1057-1065
Author(s):  
Kai Huang ◽  
Subhasis Misra ◽  
Riccardo Lemini ◽  
Yong Chen ◽  
Leigh L. Speicher ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document